Device/Diagnostics Quarterly Deal Statistics, Q4 2015

 
• By Maureen Riordan and Amanda Micklus

At $1.2 billion, Q4 device financing was the second-lowest quarter of 2015; M&A dollar volume was also low, but included multiple deals across various cardiovascular markets. Diagnostics financing was also down in Q4, totaling $403 million; acquisitions were worth $441 million.

Device companies raised a total of $1.2 billion in financing in the fourth quarter, a 16% decrease from Q3's $1.4 billion. Q4 turned out to have the second-lowest financing aggregate of the year, only ahead of the first quarter's $934 million. However, the medtech industry had a strong 2015 in terms of overall figures and brought in a total of $5.4 billion, a 35% increase over 2014's $4 billion (which had been flat from 2013). (See Exhibit 1.)

The largest single transaction of Q4 was also the quarter's lone initial public offering – Novocure Ltd.'s $161 million...

More from Deal-Making

More from In Vivo

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 
• By Bridget Silverman

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By Jo Shorthouse

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.